BioNTech SE
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +3.6% | -3.3% | -0.1% | +0.7% | +0.6% | -6.0% | +2.1% | -1.4% | +3.0% | -4.0% | -3.6% | |
| – | +4.2% | -6.4% | +0.0% | +1.1% | +1.7% | -16.9% | +1.9% | -0.6% | +2.0% | -3.7% | -1.7% | |
| – | -13.6% | -23.0% | +15.6% | -7.2% | +1.4% | +4.3% | +0.8% | -1.7% | -24.0% | +29.7% | -2.1% | |
| – | +5.1% | -5.3% | +10.4% | -3.4% | +0.4% | -15.9% | -0.5% | +3.5% | +2.1% | -1.2% | -33.5% | |
| – | +7.6% | -10.9% | -85.1% | +318.2% | +27.2% | -32.6% | +40.9% | -51.6% | +40.7% | -37.8% | -60.0% | |
| – | -14.0% | -3.4% | -1.5% | -10.9% | -6.5% | -10.2% | -9.3% | -2.2% | -51.0% | -6.1% | -3.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -0.8% | +1.7% | +1.0% | +0.4% | +1.8% | -1.2% | -3.1% | -1.8% | +2.8% | +0.9% | +0.6% | |
| – | +17.5% | +5.1% | +4.9% | +1.3% | -9.6% | +91.2% | -1.6% | -6.5% | +15.5% | -3.5% | -8.2% | |
| – | +17.9% | -17.1% | +38.3% | +3.8% | -5.1% | -27.7% | +38.9% | -8.6% | -3.5% | -13.9% | +8.6% | |
| – | +14.6% | -22.4% | +51.1% | +4.0% | +0.0% | -39.2% | +20.6% | +20.1% | -3.6% | -17.5% | +10.3% | |
| – | -29.8% | +11.4% | +12.8% | +5.9% | +5.6% | +40.5% | -5.6% | +1.9% | -2.3% | +8.8% | +0.7% | |
| – | +59.0% | -15.6% | +195.0% | -13.5% | -44.0% | +4.0% | +13.6% | -20.7% | +33.7% | -12.2% | +37.7% | |
| – | +18.0% | +7.3% | +7.0% | -5.9% | +4.1% | +10.6% | -8.5% | -11.6% | +12.1% | +14.4% | +5.2% | |
| – | +1.9% | -1.4% | -4.5% | +0.2% | +1.6% | -2.5% | -2.2% | -0.2% | +4.0% | -2.6% | -5.2% | |
| – | +2.4% | -1.6% | -4.2% | +1.1% | +1.4% | -2.2% | -2.1% | -0.2% | -1.7% | -2.8% | -4.8% | |
| – | +0.5% | -0.2% | -1.2% | +2.9% | -1.8% | +0.0% | +0.5% | -1.0% | +2.5% | +3.2% | +0.2% |
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.